Lantheus Holdings (LNTH) Liabilities and Shareholders Equity (2014 - 2026)

Lantheus Holdings (LNTH) posted quarterly Liabilities and Shareholders Equity of $2.3 billion for Q1 2026, up 14.18% YoY from $2.1 billion in Q1 2025, and up 5.35% sequentially from $2.2 billion in Q4 2025.

Lantheus Holdings (LNTH) Liabilities and Shareholders Equity (2014 - 2026) Analysis & Trends

Lantheus Holdings has disclosed Liabilities and Shareholders Equity across 13 years of filings, most recently posting $2.3 billion for Q1 2026.

  • In Q1 2026, Liabilities and Shareholders Equity rose 14.18% year-over-year to $2.3 billion; the TTM figure through Mar 2026 stood at $9.0 billion (up 11.73% YoY), while the FY2025 annual figure was $2.2 billion, up 12.48% from the prior year.
  • Liabilities and Shareholders Equity advanced to $2.3 billion in Q1 2026, from $2.2 billion in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for LNTH reached as high as $2.3 billion in Q1 2026 and fell as low as $933.2 million in Q1 2022.
  • The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2024), against an average of $1.7 billion.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 52.96% — and 2025, when it increased 9.09%.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.3 billion in 2022, then grew by 24.97% to $1.7 billion in 2023, then climbed by 19.94% to $2.0 billion in 2024, then grew by 12.48% to $2.2 billion in 2025, then grew by 5.35% to $2.3 billion in 2026.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $2.3 billion, $2.2 billion, and $2.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Teva Pharmaceutical Industries 38.67 Bn 34.93 Bn 1.97 Bn 40.04 Bn
2 Zoetis 30.59 Bn 28.65 Bn 1.62 Bn 15.15 Bn
3 RedHill Biopharma 26.22 Bn 26.22 Bn - -
4 United Therapeutics 23.80 Bn 21.65 Bn 648.10 Mn 6.71 Bn
5 Curaleaf Holdings 23.70 Bn 23.70 Bn 157.29 Mn -
6 Viatris 18.69 Bn 16.89 Bn 1.16 Bn 36.83 Bn
7 Neurocrine Biosciences 16.86 Bn 15.54 Bn 800.70 Mn 4.91 Bn
8 Elanco Animal Health 11.99 Bn 11.57 Bn 785.00 Mn 13.22 Bn
9 Dr Reddys Laboratories 11.65 Bn 11.51 Bn - 6.18 Bn
10 Lantheus Holdings 78.78 Mn -419.80 Mn 230.92 Mn 2.35 Bn

Historic Data

Download Data
DateValue
Mar 31, 2026 2.35 Bn
Dec 31, 2025 2.23 Bn
Sep 30, 2025 2.28 Bn
Jun 30, 2025 2.12 Bn
Mar 31, 2025 2.06 Bn
Dec 31, 2024 1.98 Bn
Sep 30, 2024 2.05 Bn
Jun 30, 2024 1.94 Bn
Mar 31, 2024 1.83 Bn
Dec 31, 2023 1.65 Bn
Sep 30, 2023 1.52 Bn
Jun 30, 2023 1.34 Bn
Mar 31, 2023 1.35 Bn
Dec 31, 2022 1.32 Bn
Sep 30, 2022 1.10 Bn
Jun 30, 2022 1.01 Bn
Mar 31, 2022 933.17 Mn
Dec 31, 2021 863.78 Mn
Sep 30, 2021 847.82 Mn
Jun 30, 2021 857.80 Mn